GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioAtla Inc (NAS:BCAB) » Definitions » Shares Outstanding (EOP)

BioAtla (BioAtla) Shares Outstanding (EOP) : 48.08 Mil (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is BioAtla Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. BioAtla's shares outstanding for the quarter that ended in Dec. 2023 was 48.08 Mil.

BioAtla's quarterly shares outstanding increased from Sep. 2023 (47.91 Mil) to Dec. 2023 (48.08 Mil). It means BioAtla issued new shares from Sep. 2023 to Dec. 2023 .

BioAtla's annual shares outstanding increased from Dec. 2022 (47.55 Mil) to Dec. 2023 (48.08 Mil). It means BioAtla issued new shares from Dec. 2022 to Dec. 2023 .


BioAtla Shares Outstanding (EOP) Historical Data

The historical data trend for BioAtla's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioAtla Shares Outstanding (EOP) Chart

BioAtla Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shares Outstanding (EOP)
Get a 7-Day Free Trial 21.59 33.66 37.29 47.55 48.08

BioAtla Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 47.55 47.64 47.80 47.91 48.08

Competitive Comparison of BioAtla's Shares Outstanding (EOP)

For the Biotechnology subindustry, BioAtla's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioAtla's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioAtla's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where BioAtla's Shares Outstanding (EOP) falls into.



BioAtla Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


BioAtla  (NAS:BCAB) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


BioAtla Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of BioAtla's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


BioAtla (BioAtla) Business Description

Traded in Other Exchanges
N/A
Address
11085 Torreyana Road, San Diego, CA, USA, 92121
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise Mecbotamab vedotin, Ozuriftabmab vedotin, BA3071, and Bispecific antibody programs.
Executives
Sylvia Mcbrinn director
Short Jay M Phd director, 10 percent owner, officer: Chief Executive Officer C/O DIVERSA CORPORATION, 4955 DIRECTORS PLACE, SAN DIEGO CA 92121
Christian Vasquez officer: See Remarks 121 E. PALOMAR STREET, CHULA VISTA CA 91911
Lawrence Steinman director 10555 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121
Eddie Williams director 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080
Scott Andrew Smith director, officer: President C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Eric Sievers officer: Chief Medical Officer 11085 TORREYANA ROAD, SAN DIEGO CA 92121
Richard A Waldron officer: Chief Financial Officer 901 MARINERS ISLAND BLVD STE.205, SAN MATEO CA 94404
Guy Levy director, 10 percent owner C/O SOLEUS PRIVATE EQUITY GP I, LLC, 104 FIELD POINT ROAD, 2ND FLOOR, GREENWICH CT 06830
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Soleus Pe Gp I, Llc 10 percent owner 104 FIELD POINT ROAD, 2ND FLOOR, GREENWICH CT 06830
Himalaya Parent Llc 10 percent owner 11085 TORREYANA ROAD, SAN DIEGO CA 92121
Susan Moran director 1232 RICHARDSON AVE, LOS ALTOS CA 94024
Carolyn Anderson Short 10 percent owner, officer: See Remarks 11085 TORREYANA ROAD, SAN DIEGO CA 92121
Priyanka Belawat director C/O ITEOS THERAPEUTICS, INC., 139 MAIN STREET, CAMBRIDGE MA 02142